553 reports of this reaction
3.5% of all TESTOSTERONE CYPIONATE reports
#5 most reported adverse reaction
PULMONARY EMBOLISM is the #5 most commonly reported adverse reaction for TESTOSTERONE CYPIONATE, manufactured by Pharmacia & Upjohn Company LLC. There are 553 FDA adverse event reports linking TESTOSTERONE CYPIONATE to PULMONARY EMBOLISM. This represents approximately 3.5% of all 15,890 adverse event reports for this drug.
Patients taking TESTOSTERONE CYPIONATE who experience pulmonary embolism should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PULMONARY EMBOLISM is moderately reported among TESTOSTERONE CYPIONATE users, representing a notable but not dominant share of adverse events.
In addition to pulmonary embolism, the following adverse reactions have been reported for TESTOSTERONE CYPIONATE:
The following drugs have also been linked to pulmonary embolism in FDA adverse event reports:
PULMONARY EMBOLISM has been reported as an adverse event in 553 FDA reports for TESTOSTERONE CYPIONATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PULMONARY EMBOLISM accounts for approximately 3.5% of all adverse event reports for TESTOSTERONE CYPIONATE, making it a notable side effect.
If you experience pulmonary embolism while taking TESTOSTERONE CYPIONATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.